Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 878 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer, Rectum Clear all
Completed Phase 1Phase 2 Interventional

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

NCT00040599
View directory record Official record
Conditions
Colorectal Cancer, Colon Cancer, Rectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumor
Interventions
hMN14 (labetuzumab)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
5
States / cities
Newport Beach, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer

NCT00077298
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
cetuximab, bevacizumab, irinotecan hydrochloride, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer

NCT00023933
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
iodine I 131 monoclonal antibody CC49-deltaCH2
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Not applicable Interventional

S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer Survivors

NCT01453452
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Pain, Psychosocial Effects of Cancer and Its Treatment, Weight Changes
Interventions
behavioral dietary intervention, exercise intervention, counseling intervention, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
58
States / cities
Tucson, Arizona • Antioch, California • Fremont, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity

NCT00003548
View directory record Official record
Conditions
Cancer
Interventions
aminocamptothecin colloidal dispersion
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer

NCT00308516
View directory record Official record
Conditions
Rectal Cancer, Cancer of the Rectum, Colorectal Cancer
Interventions
5-Fluorouracil, Bevacizumab, Radiation Therapy, Oxaliplatin, Leucovorin
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
14
States / cities
Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 22, 2026, 9:22 AM EDT
Terminated No phase listed Observational

Evaluation of Rectal Cancer Treatment Response Using PET/MRI

NCT02233595
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Chemoradiation
Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 22, 2026, 9:22 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Designing a Dyad-Based mHealth Intervention to Improve Adherence to Lifestyle Recommendations in Colorectal Cancer Survivors and Their Family Caregivers

NCT06746012
View directory record Official record
Conditions
Stage I Colon Cancer AJCC v8, Stage I Rectal Cancer AJCC v8, Stage II Colon Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Discussion, Educational Activity, Internet-Based Intervention, Interview, Medical Device Usage and Evaluation, Questionnaire Administration, Supportive Care, Survey Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 22, 2026, 9:22 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

NCT05723562
View directory record Official record
Conditions
Neoplasms, Rectal
Interventions
Dostarlimab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
7
States / cities
Los Angeles, California • Albuquerque, New Mexico • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Assessing Repeat Fit Testing for CRC

NCT03248661
View directory record Official record
Conditions
Colo-rectal Cancer
Interventions
Now I'm Telling You
Behavioral
Lead sponsor
Richard Crosby
Other
Eligibility
30 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 22, 2026, 9:22 AM EDT
Recruiting Not applicable Interventional

Efficacy and Safety of the CG-100 Intraluminal Bypass Device

NCT04184973
View directory record Official record
Conditions
Rectal Cancer, Rectal Tumor, Rectal/Anal
Interventions
CG-100 intraluminal bypass device, Stoma
Device · Procedure
Lead sponsor
Colospan Ltd.
Industry
Eligibility
22 Years to 70 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
Irvine, California • San Diego, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Colorectal Cancer Awareness, Research, Education and Screening (CARES)

NCT01804179
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Immunochemical Fecal Occult Blood Test (I-FOBT) Kit, Standard Intervention (SI) Educational Materials, CARES Intervention Educational Materials, Baseline Visit Survey, Follow-up Questionnaire
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
50 Years to 75 Years
Enrollment
514 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Not applicable Interventional Results available

Exploratory Study Of The ERCC-1 Gene

NCT00846482
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
Oxaliplatin
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Results available

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

NCT04853017
View directory record Official record
Conditions
Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
Interventions
ELI-002 2P
Drug
Lead sponsor
Elicio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 22, 2026, 9:22 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

NCT05308446
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions
Cetuximab, Encorafenib, Nivolumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
282
States / cities
Goodyear, Arizona • Carmichael, California • Dublin, California + 223 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 9:22 AM EDT
Completed No phase listed Observational

Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors

NCT01987726
View directory record Official record
Conditions
Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Breast Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
cytology specimen collection procedure, laboratory biomarker analysis
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

NCT03667716
View directory record Official record
Conditions
Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer
Interventions
COM701, COM701 with Opdivo (Nivolumab).
Drug
Lead sponsor
Compugen Ltd
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
11
States / cities
Los Angeles, California • Sarasota, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer

NCT02393755
View directory record Official record
Conditions
Colon Adenocarcinoma, Rectal Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
Capecitabine, Laboratory Biomarker Analysis, Nintedanib, Pharmacological Study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Duarte, California • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Results available

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

NCT03251378
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Colon Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Rectal Cancer
Interventions
Fruquintinib (HMPL-013)
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
9
States / cities
Phoenix, Arizona • San Marcos, California • Santa Rosa, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 22, 2026, 9:22 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

NCT07292298
View directory record Official record
Conditions
Rectal Adenocarcinoma, Rectal Cancer
Interventions
High Rare Dose Rectal Brachytherapy Boost
Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Aurora, Colorado • Rochester, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

NCT00103298
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
FOLFOX regimen, fluorouracil, isolated perfusion, leucovorin calcium, melphalan, oxaliplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Not applicable Interventional

Energy Balance Interventions for Colorectal Cancer Prevention

NCT00653484
View directory record Official record
Conditions
Colorectal Cancer, Obesity
Interventions
Physical Activity, Energy Restriction, Physical Activity and Energy Restriction
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer

NCT00003427
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions
irinotecan hydrochloride, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 22, 2026, 9:22 AM EDT
Active, not recruiting Phase 2 Interventional

Organ Preservation in Early Rectal Cancer Patients

NCT03548961
View directory record Official record
Conditions
Rectal Cancer
Interventions
FOLFOX regimen
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 9:22 AM EDT